Napo, Salix Pharmaceuticals Inc. gastrointestinal news
Salix said a jury in the Supreme Court of the State of New York for the County of New York found that Salix complied with its obligations under a 2008 deal with Napo to commercialize Fulyzaq crofelemer in the U.S. and thus did not breach the deal. In 2011, Napo filed the suit alleging Salix breached the 2008 deal by "unnecessarily stalling the advancement" of the diarrhea drug and was seeking damages. The deal gave Salix rights to crofelemer in North America, Japan and Europe, excluding Liechtenstein, Norway and Switzerland. Salix markets the product as Fulyzaq in the U.S. to treat non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy. The company did not break out 2013 Fulyzaq sales. FDA approved Fulyzaq in December 2012. Napo could not be reached for comment (see BioCentury, May 16, 2011; Nov. 21, 2011 & Nov. 11, 2013). ...